Mutation analysis of APC gene in gastric cancer with microsatellite instability

Dian-Chun Fang, Yuan-Hui Luo, Shi-Ming Yang, Xiao-An Li, Xian-Long Ling, Li Fang

INTRODUCTION

The mechanisms of carcinogenesis in the gastric mucosa remain unclear. Adenomatous polyposis coli or APC, has been characterized as a tumor suppressor gene and considered a “gatekeeper” because alterations in this gene occur as an early event in the neoplastic transformation[7-10]. The APC gene was first identified in the germline of individuals with the condition known as familial adenomatous polyposis or FAP[11] and has been shown to play a role in the development of sporadic colorectal cancer[12-14]. Studies have attempted to characterize the mutation of APC in sporadic gastric cancer[7,10] and in a limited number of familial gastric cancer[7,12]. It has been found that inactivation of APC plays a role in the development of some gastric cancers, particularly very well differentiated adenocarcinomas and signet-ring cell carcinomas[13,14], and that the mutations of the APC gene, similar to those in colorectal tumorigenesis, occur during the early stages of gastric adenoma development[15,16]. Genetic instability is strongly involved in neoplastic transformation and progression[17]. In gastrointestinal carcinomas, such genetic instability may be classified into two different forms in which hypermutability occurs either by means of chromosomal instability or microsatellite instability (MSI)[18-21]. MSI represents an important new form of genetic alteration characterized by widespread instability in repetitive nucleotide sequences. MSI has been found in the majority of tumors associated with hereditary non-polyposis colorectal cancer (HNPCC)[22,23] in which germ-line mutation occurs within the mismatch repair genes hMSH2, hMLH1, hPMS2 or hMSH6[24-28]. Mutations of the transforming growth factor β receptor gene (TGF-βRI), and BAX gene are strongly correlated with MSI[29,31]. MSI is also a distinctive feature in about 10-15 % of sporadic colorectal tumors and to a varying degree in tumors of other organs, including the stomach[22-24]. Although mutations of APC have been reported in gastric cancer, less clear, however, is the relevance of APC mutation as a potential factor in MSI-positive gastric cancer. The aim of the present study is to correlate APC mutation with MSI in gastric carcinomas.

MATERIALS AND METHODS

Tissue samples

Sixty-eight cancer and corresponding normal tissues were obtained from surgically resected gastric carcinoma in Southwest Hospital. Each specimen was frozen immediately and stored at -80 °C until analyzed. A 5μm section was cut from each tissue and stained with hematoxylin/eosin in order to confirm whether the cancer cells in tissues were predominant or not. Genomic DNA was isolated by standard proteinase-K digestion and phenol-chloroform extraction protocols. Of the 68 patients with gastric cancer, 45 were men and 23 were women with an age range of 30-76 years (mean age of 56.2 years at diagnosis). None of the patients included in the present series had a family history suggestive of HNPCC and had received chemotherapy or radiation therapy.

Multiplex PCR

Multiplex PCR was utilized in order to visualize the product of several regions simultaneously. Singleplex PCR was also used to help confirm cases and for regions that were difficult to amplify. Multiplex PCR analysis of APC exon 15 was performed using primers with a GC clamp (Table 1). Genomic DNA(100-400 ng), 0.25 μM primer for multi-primer reaction,
1×buffer, 1.5 mM MgCl₂, 0.25 mM of each dNTPs, and 0.1 U/µl Amplitaq Gold were combined in 10 µl reaction. The PCR reaction consisted of a denaturation step at 95 °C for 12 minutes followed by 32 cycles of 40 seconds at 94 °C, 60 seconds at 49 °C, and 90 seconds at 72 °C. Elongation occurred through 10 minutes at 72 °C, 10 minutes at 98 °C, 30 minutes at 50 °C and 30 minutes at 37 °C.

**Denaturing gradient gel electrophoresis (DGGE)**

DGGE analysis was performed for scanning mutations at 15 exon of APC gene. 8 µl of each sample was loaded on the gels consisting of 10 % polyacrylamide and 10-60 % urea-formamide. The gels were run at 90V for 17 hours in tanks of buffer at 50 °C. Gels were stained with 0.5 µl Sybr Green I and Sybr Green II for 20 minutes and visualized by UV transillumination. Heteroduplex samples were further analyzed by manual sequencing.

**Manual sequencing**

Samples were amplified for sequencing with PCR primers that did not include the GC clamp (Appendix A). The PCR reaction included 200-400 ng of genomic DNA, 0.25 µM primer, 1×buffer, 1.5mM MgCl₂, 0.25mM of each dNTPs, and 2.5U Amplitaq Gold were combined in a 1 µl reaction. The PCR reaction consisted of a denaturation step at 94 °C for 3 minutes followed by 35 cycles of 60 seconds at 94 °C, 60 seconds at 55 °C, and 60 seconds at 72 °C. A final extension step included 10 minutes at 72 °C. 1.5 % agarose gels were run at 150V to confirm the existence of PCR product. The product was purified following the instructions of the Wizard PCR Preps DNA Purification System (Promega, Madison, WI). Following the purification process, the product was run on a 1.5 % agarose gel at 150V to verify the product. Sequencing was performed following the instruction of the system. The film was read independently by two individuals according to the APC sequence.

### Table 1  Primer Sequences used in APC mutation analysis

| Exon | GC Clamp | Primer Sequences | Size (bp) |
|------|----------|------------------|-----------|
| 15.1 | 2/0      | F-TTCAGGCAAATCCTAAGAGA/R-TTGAGCCAGGAGA CATATAA | 329       |
| 15.2 | 0/2      | F-GGAATCTCATGGCAATAGG/R-TGATCATCTGGAATGTC | 284       |
| 15.3 | 2/0      | F-AGCAGATCGTCCATGATGA/R-TGACAGTCTCTCCGAGCTTT | 387       |
| 15.4 | 0/2      | F-CTCAATCATCCAGCAACAGAAA/R-TGGCATAGAGGAATA | 312       |
| 15.5 | 2/0      | F-AAGCTGTGCTGCCATAC/R-CTGAGTCGCTGTGTTAGGA | 282       |
| 15.6 | 2/5      | F-CTATGCGCATTGAAATAC/R-CTAGTCGTATCTCATGTATAA | 306       |
| 15.7 | 7/5      | F-ATGATGGAAGAGTTAGA/R-ATCAGTGCTGCTGATTGAA | 253       |
| 15.8 | 7/5      | F-AGAGCCCAAACACATATAG/R-TCATTTTGGAGGCTTCT | 327       |
| 15.9 | 2/0      | F-AAATCAGATGGTTCTTAATC/R-TTCTCAGCTGTGAAAGCAT | 355       |
| 15.10| 2/6      | F-CAAGCTATTTGATTATG/G-AACATTTGGAGTCTTCT | 344       |
| 15.11| 2/6      | F-TTAACCAGAAACAAATACAG/R-CTCGACAGCAAGATCTT | 320       |
| 15.12| 2/0      | F-GGAACAGTCTCTCAGTATAG/R-TATGCTGCTCTTCT | 287       |
| 15.13| 2/5      | F-GAATCTCATGGCAACAGAAGAA/RCATTTTGGAGGCTTCT | 310       |
| 15.14| 2/6      | F-TGGTAAGTGGTACCTTAGA/R-AGATCGACAGCTGAAAGA | 279       |
| 15.15| 5/2      | F-AAACACCAGCAAGATCTT/R-AGGCTGTCTCAGTGT | 335       |
| 15.16| 2/5      | F-CGATGAGGCACATTATCA/R-CTTGCGTCTACGATGAC | 291       |
| 15.17| 4/2      | F-ATTATTCTGCTCTGCAAC/R-CTGATGTGGTGATTACACATTA | 300       |
| 15.18| 2/6      | F-TGCCACCGGTGTATGTTGRT/R-TTCTCCTTTGCGGATGAC | 351       |
| 15.19| 4/2      | F-GGTGATTTCTATGCAGATG/R-CACGCTGCTCTATGATCA | 351       |
| 15.20| 2/0      | F-GAAACAAACTTCAACATGAA/R-AATGAGCGTTGATGATGAG | 378       |
| 15.21| 2/0      | F-AGCTGCCAAAATCAGTAA/R-TATTCTGCTGCTGAGT | 342       |
| 15.22| 2/6      | F-GTAAAGTTACAGCCACAC/R-CTGTTGCAATCTGACAG | 342       |
| 15.23| 2/0      | F-CCAGTCCATCAAGAGCATC/R-CAACAGTGCATCTGAGT | 351       |
| 15.24| 2/5      | F-TCACAGGGAGACCAAGTGA/R-TTGGACCTTCTCAGTGAC | 327       |
| 15.25| 2/3      | F-ATGGTGGCATTAGGTGAG/R-CTGCTGCTCATTAGC | 306       |

GC clamp: 1=CGCCCGCGCGCGGCGGCGGCGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG; 2=CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG; 3=CG; 4=GCGCG; 5=CGTCCGGCG; 6=GCGCGGTCCGGCGCC; 7=CGCCCGCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG.
**MSI detection**

MSI analyses included five microsatellite markers: BAT25, BAT26, BAT40, D2S123, and D5S346. PCR was performed as previously described [35]. MSI was defined as the presence of band shift in the tumor DNA that was not present in the corresponding normal DNA. Based on the number of mutated MSI markers in each tumor, carcinomas were characterized as MSI-H if they manifested instability at two or more markers, MSI-L if unstable at only one marker, and MSS if they showed no instability at any marker.

**Statistical analysis**

Chi-square test with Yates’ correction was used. A \( P \) value <0.05 was considered significant.

**RESULTS**

Multiplex PCR and DGGE were used to scan the mutation at the exon 15 of APC in 68 gastric cancers (Figure 1). The samples that showed alterations by DGGE were further analyzed through manual sequencing (Figure 2). APC mutations were detected in 15 samples (22.1%) held APC mutations that lead to premature protein truncation (Table 2). The truncation of the protein occurred as a result of a stop codon created through a base pair change, an insertion, or a deletion.

We compared mutation of exon 15 of APC gene in gastric cancer with various clinicopathological parameters including tumor size, differentiation, TNM status, clinical stage and Lauren’s types. Table 3 shows the association of mutations of APC to the clinicopathological parameters of 68 gastric carcinomas. Mutations of APC gene were observed more common in intestinal type than in diffuse type tumors (\( P <0.05 \)).

Alterations of electrophoretic patterns of PCR products of five microsatellite markers were compared between tumor and normal DNA in each patient. MSI affecting at least one locus was observed in 17 (25 %) of 68 tumors, among which eight (11.8 %) were MSI-H, nine (13.2 %) were MSI-L, and fifty-one (75 %) were MSS. Table 4 shows the association of mutations of APC to MSI of 68 gastric carcinomas. Three mutations were found in 9 tumors with MSI-L and 12 were found in 51 tumors with MSS, and no mutation was found in 8 tumors with MSI-H.

**Table 2** APC mutation in 12 gastric carcinomas

| Exon region | Nucleotide alteration | Nucleotide location | Codon number |
|-------------|----------------------|--------------------|--------------|
| 15.4        | C→A                  | 2893               | 940          |
| 15.5        | insA                 | 2866               | 935          |
| 15.10       | del A                | 3835 or 3836       | 1258         |
| 15.11       | del AAAA              | 3981               | 1307         |
| 15.12       | del AAAGA             | 3988               | 1309         |
| 15.13       | delT                 | 4146               | 1362         |
| 15.13       | delGT                | 4245               | 1398         |
| 15.13       | delT                 | 4282               | 1407         |
| 15.14       | G→T                  | 4410               | 1450         |
| 15.14       | G→T                  | 4452               | 1464         |
| 15.15       | delAG                | 4455               | 1465         |
| 15.19       | insCT                | 5326               | 1755         |
| 15.21       | insT                 | 5596               | 1845         |
| 15.22       | delG                 | 5940               | 1960         |

**Table 3** The relationship between the APC mutation and clinicopathological parameters

| Parameters                | N.o. of cases | APC mutation |
|---------------------------|---------------|--------------|
| Size                      |               |              |
| <5cm                      | 31            | 7            |
| >5cm                      | 37            | 8            |
| Differentiation           |               |              |
| Well                      | 14            | 4            |
| Moderate                  | 20            | 6            |
| Poor                      | 28            | 3            |
| Mucinous                  | 6             | 2            |
| Lauren classification     |               |              |
| Intestinal type           | 30            | 10\*         |
| Diffuse type              | 38            | 5            |
| Serosal invasion          |               |              |
| Absent                    | 30            | 6            |
| Present                   | 38            | 9            |
| Metastasis                |               |              |
| Absent                    | 33            | 8            |
| Present                   | 35            | 7            |
| Clinical stage            |               |              |
| I and II                  | 36            | 9            |
| III and IV                | 32            | 6            |

\*\( P <0.05 \) vs diffuse type

**Table 4** The relationship between MSI and APC mutation

| MSI status | No. of cases | APC mutation |
|------------|--------------|--------------|
| MSI-H      | 8            | 0            |
| MSI-L      | 9            | 2            |
| MSS        | 51           | 13           |
DISCUSSION
Mutations of APC gene have been shown to play an important role in colorectal tumorigenesis. A germline mutation in APC contributes significantly to the development of colitis-associated neoplasia\(^{[30]}\). In the current study, we investigated mutations of the APC gene in 68 gastric carcinomas obtained surgically. Mutations at exon 15 of APC gene were detected in 22.1% of gastric cancers. This finding is similar to the previous studies\(^{[31,32]}\). This proportion may be an underestimate because the mutation of exons 1 through 14 were not detected in this study. Previous investigations have found that the 5’ half of APC holds the majority of the germline mutations\(^{[33,37]}\). The mutations identified in the study were spread throughout the exon 15 of APC sequence. Sequencing analysis confirmed that the mutations resulted in truncation of the gene products or in an amino acid change. The APC gene encodes a large protein with multiple cellular functions and interactions. Mutations in this gene would lead to alterations in signal transduction of cell differentiation, mediation of intercellular adhesion, stabilization of the cytoskeleton and possibly regulation of the cell cycle and apoptosis\(^{[38,39]}\). Our results imply that APC plays a crucial role in gastric carcinogenesis, as was observed in colorectal carcinogenesis.

In the current study, we did not find an obvious relationship between the APC mutation and tumor size, depth of invasion, node metastasis or clinical stages, indicating a limited role of the APC mutation in predicting prognosis of gastric carcinomas. This finding is in agreement with the recently published data on cholangiocarcinoma and breast cancer\(^{[40,41]}\). Gastric carcinomas can be divided into “intestinal” type and “diffuse” type. The intestinal type of gastric cancer is the predominant type in elderly population at high risk and preceded by well-defined precancerous lesions, such as intestinal metaplasia and atrophic gastritis. The diffuse type is relatively more frequent in low risk populations and is not as often preceded by intestinal metaplasia. A distinct genetic pathway exists in gastric carcinogenesis of different histological subtypes and their tumor progression\(^{[42-45]}\). Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene were present in intestinal type gastric cancer\(^{[46,47]}\), whereas epigenetic inactivation of E-cadherin via promoter hypermethylation may be an early critical event in the development of undifferentiated tumors\(^{[46,47]}\). In this study, marked difference in APC mutation was noted in gastric cancer by histological type. APC mutations were significantly more frequent in intestinaltype gastric cancers as compared with diffuse-type gastric cancers, suggesting that APC gene is not only a predisposing gene in colorectal cancer but also a predisposing gene in intestinal type of gastric cancer. The mutation of APC gene may be considered makers for intestinal or colonic differentiation. The mutation of APC in the majority of intestinal type cancers also supports the theory that these cancers result from transformation of intestinal metaplasia.

There is evidence that MSI cancer comprises distinctive MSI-H and MSI-L categories\(^{[14]}\). MSI-H cancers are distinguished clinicopathologically and in their spectrum of genetic alterations from cancers showing MSI-L and MSS cancers\(^{[14]}\). Our previous studies indicated that MSI-H gastric cancers often show lower frequency of LOH of APC, MCC and DCC genes than do MSI-L and MSS cancers\(^{[41]}\). In present study, 15 APC mutations were all detected in MSI-L and MSS, but no mutation was found in those showing MSI-H. This result indicates that APC is mutational target in MSI-L and MSS tumors cells and support the notion that APC mutation-positive tumors may identify an alternative pathway which is probably different from MSI-related phenomenon observed in HNPCC. Our analysis of APC mutation should further provide some clues to the molecular mechanisms underlying the profound genomic instability in the MSI and LOH pathway for gastric carcinoma.

REFERENCES
1. Groden J, Gelbert L, Thiliveris A, Nelson L, Robertson M, Joslyn G, Samowitz W, Spiro L, Carlson M, Burtt R, Leppert M, White R. Mutational analysis of patients with adenomatous polyposis: identical inactivating mutations in unrelated individuals. Am J Hum Genet 1993;52:263-272
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170
3. Mulken J, Poncin J, Arends J, De Goeij AF. APC mutations in human colon adenomas: analysis of the mutation cluster region with temperature gradient gel electrophoresis and clinicopathological features. J Pathol 1998;185:360-365
4. Groden J, Thiliveris A, Samowitz W, Carlson M, Gelbert L, Albertsens H, Joslyn G, Stevens J, Spiro L, Robertson M, Saxegard L, Krappcho K, Wolff E, Burtt R, Hughes JP, Warrington J, McPherson J, Wasumuth J, Passler DL, Abderrahim H, Cohen D, Leppert M, White R. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:789-805
5. van Wyk R, Stegak P, Kotze MJ, Jaramillo E, Koizumi K, Grobbelaar AJ. Multiple APC mutations in sporadic flat colorectal adenomas. Eur J Hum Genet 1999;7:928-932
6. Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, Cameron J, Hruban RH. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/ beta-catenin pathway and chromosome 11p. Am J Pathol 2001;159:1619-1627
7. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagae H, Kato Y, Yanagisawa A, Tsugita E, Nakamura Y. The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 1992;52:3231-3233
8. Sud R, Wells D, Talbot IC, Delhanty JD. Genetic alterations in gastric cancers from British patients. Cancer Genet Cytogenet 2001;126:111-119
9. Sud R, Talbot IC, Delhanty JD. Infrequent alterations of the APC and MCC genes in gastric cancers from British patients. Br J Cancer 1996;74:1104-1108
10. McKie AB, Filipe M, Lemoine NR. Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. Int J Cancer 1993;55:598-603
11. Nakatsu S, Kaku H, Mihara M, Itoh F, Adachi Y, Ohara M, Hosokawa I, Maim K. Absence of microsatellite instability and germline mutations of E-cadherin, APC and p53 genes in Japanese familial gastric cancer. Tumour Biol 2001;22:262-268
12. White S, Bubb VJ, Wylie AH. Germline APC mutation (Gln1317) in a cancer-prone family that does not result in familial adenomatous polyposis. Genes Chromosomes Cancer 1996;15:122-126
13. Ebert F, Gehmann S, Muller O, Yu J, Sung JJ, Malferttheiner P. Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. J Cancer 2002;23:87-91
14. Nakatsu S, Yanagisawa A, Ichii S, Tahara E, Kato Y, Nakamura Y, Horii A. Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differ-entiated adenocarcinoma and signet-ring cell cancer. Hum Mol Genet 1994;3:559-563
15. Tamura G, Maesawa C, Suzuki Y, Tamada H, Satoh M, Ogasawara S, Kashiwaba M, Satodate R. Mutations of the APC gene occur during early stages of gastric adenoma progression. Cancer Res 1994;54:1149-1151
16. Nakatsu S, Yanagisawa A, Furukawa Y, Ichii S, Kato Y, Nakamura Y, Horii A. Somatic mutations of the APC gene in precancerous lesion of the stomach. Hum Mol Genet 1993;2:1463-1465
Fang DC et al. Mutation of APC gene in gastric cancer

17 Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 632-637

18 Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819

19 Ionov Y, Pienado MA, Malkhosyan S, Shibata D, Perucchini M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Natl 1993;363:558-561

20 Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525-532

21 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767

22 Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sisenon P, Kinzler KW, Vogelstein B, Hamilton SR. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-221

23 White RL. Tumor suppressing pathways. Cell 1995;89:591-592

24 Aaltonen LA, Peltomaki P, Leach FS, Sisenon P, Liflingan M, Mcklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-816

25 Wu BP, Zhang YL, Gao Z, Ehrlich SM, Fields JZ, Boman PH, Pinsky SJ, Foukies WD. The effect of the 11307 APC polymorphism on the dinocryptological features and natural history of breast cancer. Br J Cancer 1999;81:850-854

26 Wu MS, Chang MC, Huang SP, Tseng CC, Sheu JC, Lin YW, Shun CT, Lin MT, Lin JT. Correlation of histologic subtypes and replication error phenotype with comapara-tive genomic hybridization in gastric cancer. Gene Chromosomes Cancer 2001;30:80-86

27 Wang SY, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1999;112:1467-1465

28 Endoh Y, Sakata K, Tamura G, Ohmura K, Ajioka Y, Watanabe H, Motoyama T. Cellular phenotypes of differentiated-type adenocarcinomas and precancerous lesions of the stomach are dependent on the genetic pathways. J Pathol 2000;191:257-263

29 Ohmura K, Tamura G, Endoh Y, Sakata K, Takahashi T, Motoyama T. Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. Hum Pathol 2000;31:1031-1035

30 Ebert MP, Fei G, Kahmann S, Muller O, Yu J, Sung J, Malfertheiner P. Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 2002;23:87-91

31 Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999;59:4275-4289

32 Tamura G, Sato K, Akiyama S, Tsutuiya T, Endoh Y, Usuba O, Kimura W, Nishizuka S, Motoyama T. Molecu lar characterization of undifferentiated-type gastric carcinoma. Lab Invest 2001;81:593-598

33 Becker BF, Atkinson M, Reich U, Becker I, Nekarda H, Sewert JR, Hofler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-3852

34 Ascano J Jr, Frierson H Jr, Moskaluk CA, Harper J, Roviello F, Jackson CE, El-Rifai W, Vindigni C, Tosi P, Powell SM. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 2001;14:942-949

35 Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Claudia C, Secura R, Carneiro F, Sobrinho-Simoes M. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2003;20:1525-1528

Edited by May